Header Logo

Connection

Kathleen Moore to Molecular Targeted Therapy

This is a "connection" page, showing publications Kathleen Moore has written about Molecular Targeted Therapy.
Connection Strength

0.947
  1. Niraparib in the treatment of previously treated advanced ovarian, fallopian tubeĀ or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
    View in: PubMed
    Score: 0.629
  2. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
    View in: PubMed
    Score: 0.155
  3. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018 03; 148(3):591-600.
    View in: PubMed
    Score: 0.131
  4. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.